

## Abrysvo keeping RSV low in older adults and in pregnancy

	OLDER ADULTS	PREGNANCY
Indication	For <b>individuals age 60+</b> , to prevent lower respiratory tract disease caused by RSV  NACI suggests either Abrysvo or Arexvy may be recommended for older adults. The need for booster doses is not yet clear.	For <b>pregnant individuals (32-36 wks gestational)</b> to prevent lower respiratory tract disease caused by RSV in infants from birth to 6 months of age. Needs to be given at least 2 weeks before birth to allow for transfer of protective antibodies.  <b>NACI advises Beyfortus is recommended over Abrysvo</b> due to Beyfortus' superior efficacy, duration of protection, and available safety data. If Abrysvo is given during pregnancy: <ul style="list-style-type: none"> <li>▪ Beyfortus is not recommended to be given to healthy infants.</li> <li>▪ Beyfortus is still recommended if infant at high risk, or if Abrysvo received less than 2 weeks before delivery</li> </ul>
Efficacy	Reduce risk of lower respiratory tract disease with 3 or more symptoms by 77.8%	Reduce infant hospital admission due to RSV by 57% <sup>2</sup> Reduce medically attended visit for infant due to RSV by 51% <sup>2</sup>
Rare side effects	Atrial fibrillation, Guillain Barre Syndrome, Miller Fisher Syndrome	No increased risk of severe events in infants or pregnant people compared to placebo <sup>2</sup> Infants: Preterm birth*, low birth weight, jaundice
Common side effects	Pain at injection site, fatigue, headache, muscle or joint pain	Pain at injection site, headache, myalgia
Dosing	0.5 mL IM (deltoid) x 1 dose Vaccination should be postponed in individuals suffering from an acute febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccine.	
Allergens	Polysorbate 80 Latex-free	
Administration	Single-use vial, requires reconstitution with provided diluent Use within 4h after reconstitution	
Interactions	NACI suggests Abrysvo can be administered at the same time as, or at any time before or after other vaccines.	
Publicly funded vaccine	<b>Eligible patients are age 60+, and:</b> <ul style="list-style-type: none"> <li>• Residents of LTC or RH</li> <li>• Receiving hemodialysis or peritoneal dialysis</li> <li>• Transplant recipients</li> <li>• Experiencing homelessness</li> </ul> Identify as First Nations, Inuit, Metis	<b>Eligible patients:</b> <ul style="list-style-type: none"> <li>• Pregnant individuals (32-36 wks gestational) who will deliver near the start of or during RSV season (November-April)</li> </ul>
	<b>Order vaccine (Toronto Public Health):</b> Email orders to <a href="mailto:vaccineorder@toronto.ca">vaccineorder@toronto.ca</a> using the <a href="#">Toronto Provider RSV Vaccine Order Form</a> (updated Oct 2024)	
Cost	If patients are not eligible for publicly funded vaccine, Abrysvo is available to purchase privately from pharmacies with a prescription. (~\$280-300/dose).	

**TIP!** Be sure to include Abrysvo receipt in hospital/antenatal record

\* In some studies. This was not observed in high-income countries like Canada. It is unclear whether there is a causal relationship with the vaccine. By limiting vaccine administration to 32 through 36 weeks gestation the potential risk of preterm birth is reduced.<sup>2</sup>

### References:

1. Pfizer 2023. Abrysvo [[Product Monograph](#)]
2. NACI 2024. [Respiratory syncytial virus \(RSV\): Canadian Immunization Guide](#)
3. CDC 2023. [[For Healthcare Professionals: RSV Vaccination for Pregnant People](#)]
4. Ministry of Health (updated September 3, 2024). [RSV prevention programs](#).
5. Ministry of Health (August 14, 2024). [Older adult high-risk RSV vaccine program fact sheet – HCP](#).
6. Ministry of Health (August 8, 2024). [Infant and high-risk children RSV prevention program guidance for HCP – Abrysvo](#).
7. Toronto Public Health Physician e-Newsletter (October 24, 2024). Publicly funded RSV prevention program for infants and high-risk children.